Two new oral weight management medications are coming to the UK: the Wegovy pill (oral semaglutide) and orforglipron (UK brand name to be confirmed). Both are clinically proven treatments in tablet form. For people already on injectable treatments like Wegovy or Mounjaro, that raises a straightforward question – does it make sense to switch?
The short answer is: yes, for many people it is an option. But the right time to switch, and which pill to switch to, depends on where you are in your treatment. This guide walks through what the evidence says, what the practical differences are, and what to consider before that clinical conversation happens.
Why people consider switching
There are two main reasons people on injectables start thinking about a pill.
The first is where you are in your treatment. If you’ve reached or are approaching your clinical target weight, the question shifts from “how do I lose more?” to “how do I hold what I’ve achieved?” and it may call for a different approach.
The second is injection fatigue. Weekly injections work well clinically, but the routine – preparing the pen, finding an injection site, managing travel with medication that needs refrigeration – can add up over time.The new oral GLP-1s may mean there may be a better format for where your life is now.
What the evidence says about switching
The most relevant clinical data comes from the ATTAIN-MAINTAIN trial, published in Nature Medicine in May 2026 – the first trial to specifically test switching from an injectable to an oral medication for weight maintenance.
The trial followed two groups of people who had been on injectable treatment: those on tirzepatide (Mounjaro) and those on semaglutide (Wegovy injection). Both groups then switched to orforglipron (Foundayo).
The results were strong in both cases. People switching from semaglutide maintained 79% of their weight loss with orforglipron, compared with 38% in those who stopped active treatment. People switching from tirzepatide maintained 75%, compared with 49% on placebo.
One thing worth understanding if you’re currently on Mounjaro: tirzepatide produces higher initial weight loss than semaglutide, so there is naturally more weight to maintain when you switch. The trial shows orforglipron does that job well – but your clinical team will want to talk through what realistic expectations look like for your specific situation.
For both groups, the message is the same: switching to the pill preserved the large majority of progress achieved on the injection. Stopping treatment altogether did not.
The two oral options and how they differ
Not all oral GLP-1 medications are the same, and which one is right for you is a clinical decision, not a product choice you need to make yourself. Here’s what’s relevant to understand:
The Wegovy pill (oral semaglutide)
The Wegovy pill contains the same active ingredient as the Wegovy injection – semaglutide – but in a tablet form. It has strong headline efficacy: 16.6% mean weight loss in clinical trials. It also carries a licensed indication for cardiovascular risk reduction in people with obesity and established heart disease.
The practical consideration is the dosing protocol. The Wegovy pill needs to be taken first thing in the morning on an empty stomach, up to 120ml of plain water, and you need to wait at least 30 minutes before eating, drinking anything else, or taking other medications. This isn’t an inconvenience – it’s how the drug absorbs. Without the fasting window, the medication doesn’t work properly. Real-world data shows that around one in three people struggle to keep to this routine beyond the first month, which is why support around it matters. Your clinical team will support you in building this routine from day one.
Orforglipron (UK brand name to be confirmed)
Orforglipron is a structurally different type of medication. It’s a small-molecule drug, not a peptide, which means it doesn’t need an absorption enhancer or a fasting window. You can take it at any time of day, with or without food, alongside other medications without any timing separation required.
The headline efficacy is slightly lower than the Wegovy pill – 12.4% mean weight loss in trials – but the maintenance evidence is the strongest in the oral class. For people switching from an injectable for the purpose of holding their progress, orforglipron is the product with the most specific and robust data behind it.
It’s also the better fit for people whose daily routine makes a strict morning fasting ritual difficult – shift workers, carers, frequent travellers, or anyone on multiple daily medications.
What switching actually looks like in practice
Switching from an injectable to an oral medication isn’t a case of stopping one and starting the other the same day. There are a few things to work through with your clinical team.
Timing matters.
For people approaching their maintenance target, the switch is something to plan for once the products are available. For people who are still mid-treatment but finding the injection format difficult, the question is whether switching format mid-titration will be clinically appropriate for where you are – something the clinical team will assess at the point of prescribing.
Starting dose is clinically guided.
Switching from an injectable to an oral medication isn’t a case of stopping one and starting the other at the lowest possible dose. Your starting point on the oral medication will be determined by your clinical team, based on your current treatment and how your body has responded to injectable therapy. The titration schedule is there to ensure you reach the right maintenance dose safely – your team will guide you through it.
The fasting protocol, if relevant.
If you switch to the Wegovy pill, getting the morning routine right from day one is important. Your clinical team and Health Coaches will work through this with you in the first few weeks – not as an afterthought, but as a structured part of your onboarding onto the new medication.
Your progress is protected.
The concern most people have – “will I lose what I’ve achieved?” – is exactly what the ATTAIN-MAINTAIN trial addressed. With the right clinical product and the right support around it, the evidence says you can hold your progress. That’s what the maintenance conversation is about.
What this isn’t
Switching to a pill is not a step down in your care. You remain on the same programme, with the same clinical team and the same coach. The medication format changes. Everything around it stays the same.
It’s also not a decision you need to make on your own or based on what you’ve read elsewhere. The clinical difference between the two oral options is real and it matters – which is why it’s a proper clinical conversation.
The next step
Both products are coming to CheqUp shortly. If you’re thinking about switching, or just want to understand what the options might look like for where you are in your treatment, the best thing to do right now is make sure you’re on the list to learn more and be the first to hear when they’re available.
This article is for informational purposes. All treatment decisions are made by CheqUp’s clinical team based on your individual profile. Product availability is subject to MHRA approval.
